TY - JOUR T1 - Acceptability, willingness to use and preferred distribution models of oral-based HIV self-testing kits among key and priority populations enrolled in HIV pre-exposure prophylaxis clinics in central Uganda. A mixed-methods cross-sectional study JF - medRxiv DO - 10.1101/2022.07.27.22278119 SP - 2022.07.27.22278119 AU - John Bosco Junior Matovu AU - Roy William Mayega AU - Sylivia Nalubega AU - Jayne Byakika-Tusiime Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/07/29/2022.07.27.22278119.abstract N2 - Key Populations (KPs) and Priority Populations (PPs) taking Pre-Exposure Prophylaxis (PrEP) for HIV prevention require routine HIV testing every after three months. HIV self-testing could be an alternative testing approach for these population categories. We assessed the acceptability of oral-based HIV Self-Testing (HIVST) among Key and priority Populations taking PrEP in central Uganda. A mixed methods cross-sectional study was conducted on 367 key and priority populations attending Pre-Exposure Prophylaxis clinics in central Uganda, from May to August 2018. KPs and PPs were introduced to the Oraquick HIV self-testing kit as an option for HIV testing during their routine visit to the PrEP clinic. A demonstration of how to perform HIV self-testing was conducted using an Oraquick demonstration video and leaflet inserts after which, respondents were asked to choose between HIVST and the conventional facility blood-based HIV testing. Those willing to use the oral kit were asked to voluntarily consent, were provided with an Oraquick HIVST kit and were assisted to perform the test. Quantitative data were presented as proportions for each outcome variable. Thematic analysis was performed to explore factors that promote and inhibit HIVST. HIV self-testing acceptability; defined as the proportion of those who performed an HIVST test among those approached was 99.5% (365/367). Using an oral fluid-based kit “Oraquick” was reported to be free of pain, convenient, easy to use and time saving hence preferred over other HIV testing modalities. A multimodal approach to distributing HIV self-testing kits was suggested by respondents. Oral-based HIV self-testing is highly acceptable among key and priority populations taking Pre-Exposure Prophylaxis and can be adopted as an alternative to the conventional routine three monthly facility-based provider dependent HIV screening. Kits’ distribution may employ several models. Majority of key populations would afford the kits at a cost of not more than 1.4USD if not provided free of charge.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research was fully funded by the principal investigator and no external support was received from any organization for this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was protocol was reviewed and approved by the Busitema University Faculty of Health Sciences Higher Degrees and Research Committee and the Mbale Regional Referral Hospital Research and Ethics Committee (Ref No. MRRH-REC-IN-COM 024/2018). All respondents provided written informed consent and were free to opt out of the study at any stage of the study. Two emancipated minors aged 17 years belonging to the adolescent girls and young women category were considered for the study and written informed consent was obtained from each of their guardians before they were enrolled to participate in the studyI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified data will be made available by contacting the study PI, mtvbosco@gmail.com but is also available at https://doi.org/10.7910/DVN/XLBZXD https://doi.org/10.7910/DVN/XLBZXD ER -